皮肤神经病理:前临床与显性淀粉样神经病的生物标志物
本研究对70例TTR突变者(22例携带者、48例患者,其中66例为TTR-A97S)进行皮肤活检,测量表皮内神经纤维密度、汗腺肽能及结构蛋白PGP9.5神经支配指数和皮肤淀粉样指数。结果显示皮肤神经病理呈分期依赖性进展,感觉神经变性为早期皮肤神经病理,IENF密度在携带者中异常率最高。
要点
- 皮肤感觉神经变性是TTR-FAP前临床期的早期病理改变。
- IENF密度随FAP分期0至4逐渐下降,在携带者中异常率最高。
- SGII(VIP)从1期至2期显著降低,SGII(PGP9.5)从2期起下降。
核心结论
- 皮肤感觉与泌汗神经支配的生物标志物呈分期依赖性进展模式,感觉神经变性为早期皮肤神经病理。
研究设计与样本
- 研究纳入70例TTR突变受试者(22例携带者、48例患者),其中66例为TTR-A97S,进行皮肤活检并与临床FAP分期(0-4期)及神经生理和心理物理测试比较。
主要发现
- 携带者中皮肤去神经支配和肽能泌汗去神经支配均已明显:IENF密度从0期至4期逐渐降低。
- SGII(VIP)在1期至2期显著降低;SGII(PGP9.5)在携带者与对照间相似,但患者从2期起下降。
- 皮肤淀粉样物质在携带者中缺失,从1期起可检测到。
- 多变量混合效应模型中,皮肤淀粉样指数与SGII(PGP9.5)及分期相关。
- 所有测试中仅IENF密度、SGII(PGP9.5)和皮肤淀粉样指数与分期相关,IENF密度在携带者中异常率最高。
关键数值与推荐
- FAP分期采用0-4期评分评估临床残疾。
- 皮肤病理指标包括IENF密度、SGII(PGP9.5)、SGII(VIP)和皮肤淀粉样指数。
临床怎么用
- 皮肤活检指标(尤其IENF密度)可用于TTR-FAP携带者的早期识别和疾病进展监测。
局限性
- 样本以TTR-A97S突变为主,结论外推至其他TTR突变需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Small-fiber sensory and autonomic symptoms are early presentations of familial amyloid polyneuropathy (FAP) with transthyretin (TTR) mutations. This study aimed to explore the potential of skin nerve pathologies as early and disease-progression biomarkers and their relationship with skin amyloid deposits. METHODS: Skin biopsies were performed in patients and carriers to measure intraepidermal nerve fiber (IENF) density, sweat gland innervation index of structural protein gene product 9.5 (SGII[PGP9.5]) and peptidergic vasoactive intestinal peptide (SGII[VIP]), and cutaneous amyloid index. These skin pathologies were analyzed with clinical disability assessed by FAP stage score (stage 0-4) and compared to neurophysiological and psychophysical tests. RESULTS: There were 70 TTR-mutant subjects (22 carriers and 48 patients), and 66 cases were TTR-A97S. Skin nerve pathologies were distinct according to stage. In carriers, both skin denervation and peptidergic sudomotor denervation were evident: (1) IENF density was gradually reduced from stage 0 through 4, and (2) SGII(VIP) was markedly reduced from stage 1 to 2. In contrast, SGII(PGP9.5) was similar between carriers and controls, but it declined in patients from stage 2. Skin amyloids were absent in carriers and became detectable from stage 1. Cutaneous amyloid index was correlated with SGII(PGP9.5) and stage in a multivariate mixed-effect model. When all tests were compared, only IENF density, SGII(PGP9.5), and cutaneous amyloid index were correlated with stage, and IENF density had the highest abnormal rate in carriers. INTERPRETATION: Biomarkers of sensory and sudomotor innervation exhibited a stage-dependent progression pattern, with sensory nerve degeneration as the early skin nerve pathology. Ann Neurol 2019;85:560-573.
引用
- Chao CC, Hsueh HW, Kan HW, et al. Skin nerve pathology: Biomarkers of premanifest and manifest amyloid neuropathy. Ann Neurol. 2019. PMID: 30737830. doi:10.1002/ana.25433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。